SEARCH

SEARCH BY CITATION

References

  • 1
    Koss LG, Tiamson EM, Robbins MA. Mapping cancerous and precancerous bladder changes. A study of the urothelium in ten surgically removed bladders. JAMA 1974; 227: 2816.
  • 2
    Hartmann A, Moser K, Kriegmair M, Hofstetter A, Hofstaedter F, Knuechel R. Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. Am J Pathol 1999; 154: 7217.
  • 3
    Obermann EC, Junker K, Stoehr R, Dietmaier W, Zaak D, Schubert J, Hofstaedter F, Knuechel R, Hartmann A. Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses. J Pathol 2003; 199: 507.
  • 4
    Junker K, Boerner D, Schulze W, Utting M, Schubert J, Werner W. Analysis of genetic alterations in normal bladder urothelium. Urology 2003; 62: 11348.
  • 5
    Obermann EC, Meyer S, Hellge D, Zaak D, Filbeck T, Stoehr R, Hofstaedter F, Hartmann A, Knuechel R. Fluorescence in situ hybridization detects frequent chromosome 9 deletions and aneuploidy in histologically normal urothelium of bladder cancer patients. Oncol Rep 2004; 11: 74551.
  • 6
    Stoehr R, Zietz S, Burger M, Filbeck T, Denzinger S, Obermann EC, Hammerschmied C, Wieland WF, Knuechel R, Hartmann A. Deletions of chromosome 9 and 8p in histologically normal urothelium of patients with bladder cancer. Eur Urol 2005; 47: 5863.
  • 7
    Mazzucchelli R, Barbisan F, Stramazzotti D, Montironi R, Lopez-Beltran A, Scarpelli M. Chromosomal abnormalities in macroscopically normal urothelium in patients with bladder pT1 and pT2a urothelial carcinoma: a fluorescence in situ hybridization study and correlation with histologic features. Anal Quant Cytol Histol 2005; 27: 14351.
  • 8
    Simoneau AR, Spruck CH,III, Gonzalez-Zulueta M, Gonzalgo ML, Chan MF, Tsai YC, Dean M, Steven K, Horn T, Jones PA. Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS1 and PTC mutations. Cancer Res 1996; 56: 503943.
  • 9
    Reznikoff CA, Sarkar S, Julicher KP, Burger MS, Puthenveettil JA, Jarrard DF, Newton MA. Genetic alterations and biological pathways in human bladder cancer pathogenesis. Urol Oncol 2000; 5: 191203.
  • 10
    Stoehr R, Wissmann C, Suzuki H, Knuechel R, Krieg RC, Klopocki E, Dahl E, Wild P, Blaszyk H, Sauter G, Simon R, Schmitt R, et al. Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab Invest 2004; 84: 46578.
  • 11
    Van Rhijn BWG, Vis AN, Van der Kwast TH, Kirkels WJ, Radvanyi F, Ooms EC, Chopin DK, Boeve ER, Jobsis AC, Zwarthoff EC. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathological grade for the prediction of clinical outcome. J Clin Oncol 2003; 21: 191221.
  • 12
    Van Rhijn BW, Montironi R, Zwarthoff EC, Jobsis AC, van der Kwast TH. Frequent FGFR3 mutations in urothelial papilloma. J Pathol 2002; 198: 24551.
  • 13
    Chow NH, Cairns P, Eisenberger CF, Schoenberg MP, Taylor DC, Epstein JI, Sidransky D. Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. Int J Cancer 2000; 89: 5148.
  • 14
    Van Rhijn BWG, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 2001; 61: 12658.
  • 15
    Montironi R, Lopez-Beltran A, Mazzucchelli R, Bostwick DG. Classification and grading of the non-invasive urothelial neoplasms: recent advances and controversies. J Clin Pathol 2003; 56: 915.
  • 16
    Zaak D, Kriegmair M, Stepp H, Baumgartner R, Oberneder R, Schneede P, Corvin S, Frimberger D, Knuechel R, Hofstetter A. Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies. Urology 2001; 57: 6904.
  • 17
    EbleJN, SauterG, EpsteinJI, SesterhennIA, eds. World Health Organization Classification of Tumours. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon: IARC Press, 2004.
  • 18
    SobinLH, WittekindC, eds. TNM classification of malignant tumors. New York: Wiley-Liss, 1997.
  • 19
    Dietmaier W, Hartmann A, Wallinger S, Heinmoller E, Kerner T, Endl E, Jauch KW, Hofstadter F, Ruschoff J. Multiple mutation analyses in single tumor cells with improved whole genome amplification. Am J Pathol 1999; 154: 8395.
  • 20
    Hartmann A, Schlake G, Zaak D, Hungerhuber E, Hofstetter A, Hofstaedter F, Knuechel R. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res 2002; 62: 80918.
  • 21
    Van Oers JMM, Lurkin I, van Exsel AJA, Nijsen Y, van Rhijn BWG, van der Aa MNM, Zwarthoff EC. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res 2005; 11: 77438.
  • 22
    Hartmann A, Rosner U, Schlake G, Dietmaier W, Zaak D, Hofstaedter F, Knuechel R. Clonality and genetic divergence in multifocal low-grade superficial urothelial carcinoma as determined by chromosome 9 and p53 deletion analysis. Lab Invest 2000; 80: 70918.
  • 23
    Bakkar AA, Wallerand H, Radvanyi F, Lahaye JB, Pissard S, Lecerf L, Kouyoumdjian JC, Abbou CC, Pairon JC, Jaurand MC, Thiery JP, Chopin DK, et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 2003; 63: 810812.
  • 24
    Van Rhijn BW, van der Kwast TH, Vis AN, Kirkels WJ, Boeve ER, Jobsis AC, Zwarthoff EC. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 2004; 64: 19114.
  • 25
    Van Tilborg AAG, de Vries A, de Bont M, Groenfeld LE, van der Kwast TH, Zwarthoff EC. Molecular evolution of multiple recurrent cancers of the bladder. Hum Mol Genet 2000; 9: 297380.